Jump Financial LLC raised its position in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN – Free Report) by 73.7% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 51,747 shares of the company’s stock after buying an additional 21,962 shares during the quarter. Jump Financial LLC owned 0.12% of Viridian Therapeutics worth $1,316,000 at the end of the most recent quarter.
Other hedge funds also recently bought and sold shares of the company. VR Adviser LLC increased its holdings in shares of Viridian Therapeutics by 26.7% in the 4th quarter. VR Adviser LLC now owns 2,699,865 shares of the company’s stock valued at $78,863,000 after purchasing an additional 569,557 shares during the period. BlackRock Inc. increased its holdings in shares of Viridian Therapeutics by 39.3% in the 3rd quarter. BlackRock Inc. now owns 1,982,062 shares of the company’s stock valued at $40,653,000 after purchasing an additional 559,238 shares during the period. Vanguard Group Inc. increased its holdings in shares of Viridian Therapeutics by 31.6% in the 3rd quarter. Vanguard Group Inc. now owns 1,856,800 shares of the company’s stock valued at $38,083,000 after purchasing an additional 445,898 shares during the period. Vivo Capital LLC increased its holdings in shares of Viridian Therapeutics by 1.1% in the 4th quarter. Vivo Capital LLC now owns 1,678,207 shares of the company’s stock valued at $49,020,000 after purchasing an additional 18,188 shares during the period. Finally, State Street Corp increased its holdings in shares of Viridian Therapeutics by 159.0% in the 3rd quarter. State Street Corp now owns 1,178,549 shares of the company’s stock valued at $24,172,000 after purchasing an additional 723,484 shares during the period.
Viridian Therapeutics Stock Down 0.6 %
Shares of VRDN stock opened at $18.65 on Wednesday. Viridian Therapeutics, Inc. has a one year low of $12.80 and a one year high of $39.00. The stock has a fifty day moving average price of $23.45 and a 200 day moving average price of $27.50. The company has a quick ratio of 12.93, a current ratio of 12.93 and a debt-to-equity ratio of 0.02.
Viridian Therapeutics (NASDAQ:VRDN – Get Free Report) last issued its earnings results on Tuesday, May 9th. The company reported ($1.61) EPS for the quarter, missing the consensus estimate of ($1.00) by ($0.61). The firm had revenue of $0.10 million during the quarter, compared to the consensus estimate of $0.10 million. Viridian Therapeutics had a negative return on equity of 89.08% and a negative net margin of 10,419.10%. The firm’s revenue for the quarter was down 54.6% compared to the same quarter last year. During the same period last year, the business earned ($0.98) earnings per share. Research analysts anticipate that Viridian Therapeutics, Inc. will post -5.22 EPS for the current fiscal year.
Insiders Place Their Bets
In other Viridian Therapeutics news, insider Lara Meisner sold 2,269 shares of Viridian Therapeutics stock in a transaction on Thursday, June 15th. The stock was sold at an average price of $28.02, for a total transaction of $63,577.38. Following the completion of the transaction, the insider now directly owns 29,971 shares of the company’s stock, valued at $839,787.42. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders sold 4,643 shares of company stock worth $121,461 over the last three months. 1.43% of the stock is currently owned by corporate insiders.
Analysts Set New Price Targets
A number of equities analysts have recently weighed in on the company. Needham & Company LLC reiterated a “buy” rating and issued a $47.00 target price on shares of Viridian Therapeutics in a report on Monday, April 10th. Wedbush dropped their price objective on Viridian Therapeutics from $48.00 to $45.00 in a report on Tuesday, July 11th. BTIG Research began coverage on Viridian Therapeutics in a report on Wednesday, June 14th. They issued a “buy” rating and a $46.00 price objective on the stock. JMP Securities dropped their price objective on Viridian Therapeutics from $46.00 to $44.00 in a report on Wednesday, May 10th. Finally, Wells Fargo & Company started coverage on Viridian Therapeutics in a report on Monday, April 17th. They issued an “overweight” rating and a $46.00 price objective on the stock. Twelve research analysts have rated the stock with a buy rating, According to MarketBeat.com, Viridian Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $45.20.
About Viridian Therapeutics
Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company’s product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-002 and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.